ArticleMedical hypotheses2020
Is it possible to use Proton Pump Inhibitors in COVID-19 treatment and prophylaxis?
Article in Medical hypotheses, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Role of the SARS‑COV2 infection in the evolution of acute pancreatitis (Review).Biomedical reports · 2023Review
- Assessment of drugs administered in the Middle East as part of the COVID-19 management protocols.Inflammopharmacology · 2022Review
- Comparative risk of incidence and clinical outcomes of COVID-19 among proton pump inhibitor and histamine-2 receptor antagonist short-term users: a nationwide retrospective cohort study.BMC pharmacology & toxicology · 2022Article
- Anti-infective properties of proton pump inhibitors: perspectives.International microbiology : the official journal of the Spanish Society for Microbiology · 2022Article
- Gastrointestinal manifestations in COVID-19.Transactions of the Royal Society of Tropical Medicine and Hygiene · 2021Review
- Paradoxical relationship between proton pump inhibitors and COVID-19: A systematic review and meta-analysis.World journal of clinical cases · 2021Article
- An Additional Perspective on Proton Pump Inhibitors as Risk Factors for COVID-19.Clinical drug investigation · 2021Article
- Analysis of the Effect of Proton-Pump Inhibitors on the Course of COVID-19.Journal of inflammation research · 2021Article
- COVID-19 and Gastrointestinal Disease: Implications for the Gastroenterologist.Digestive diseases (Basel, Switzerland) · 2021Review
- Article
- The Potential Therapeutic Role of Proton Pump Inhibitors in COVID-19: Hypotheses Based on Existing Evidences.Drug research · 2020Article
- Proton Pump Inhibitors are Risk Factors for Viral Infections: Even for COVID-19?Clinical drug investigation · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coronaviruses (CoV), discovered after 1960, caused human life-threatening outbreaks. SARS-CoV2, which appeared in Wuhan, China in December 2019, causing Severe Acute Respiratory Syndrome and has different features than other coronaviruses, has been determined and the disease caused by the virus has been called "Coronavirus Disease-2019" (COVID-19). This disease activates both the natural and acquired immune system. The cytokin storm, in which blood levels of proinflammatory cytokines are detected excessively high is developing and the uncontrolled inflammatory response causes local and systemic tissue damages. Although a spesific drug has not been found yet, the medications currently in use for other indications, whose pharmacokinetic- pharmacodynamic properties and toxic doses are already known; are included in the treatment practice of COVID-19. These drugs affect the entry of the virus into the cell and its intracellular distribution. They also have anti-inflammatory and immunomodulating effects too. Therefore, we think that Proton Pump Inhibitors (PPI's) with similar mechanisms of action may also be involved in COVID-19 treatment and prophylaxis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.